MedNet.nl: In the REASSURE study, a combination treatment consisting of radium-223 and enzalutamide appears to have added value for patients with metastatic castration-resistant prostate cancer (mCRPC). A phase 3 trial, the PEACE III trial, is now underway investigating the combination in a randomized setting.
26-10-2023 | Prostate Cancer | News
ESMO 2023